在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human coagulation factor Ⅸ,FⅨ ELISA Kit

  • 中文名稱:
    人凝血因子Ⅸ(FⅨ)酶聯免疫試劑盒
  • 貨號:
    CSB-E08443h
  • 規格:
    96T/48T
  • 價格:
    ¥3600/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人凝血因子Ⅸ(FⅨ)酶聯免疫試劑盒(CSB-E08443h)為雙抗夾心法ELISA試劑盒,定量檢測樣本中的F9含量。F9基因編碼凝血因子IX,在凝血級聯反應中至關重要。其缺陷會導致B型血友病等凝血障礙疾病。研究機制上主要聚焦于開發基因療法、替代療法,以補充或修復缺陷的F9基因、糾正凝血功能,改善患者癥狀及預后。該產品可應用于凝血機制基礎研究、血友病B動物模型評估、抗凝血藥物研發中的生物標志物監測等領域,特別適用于體外實驗中對FⅨ蛋白表達水平的動態追蹤。本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    Christmas Disease ELISA Kit; Christmas factor ELISA Kit; Coagulant factor IX ELISA Kit; Coagulation factor 9 ELISA Kit; Coagulation factor IX ELISA Kit; Coagulation factor IXa heavy chain ELISA Kit; F9 ELISA Kit; FA9_HUMAN ELISA Kit; Factor 9 ELISA Kit; Factor IX Deficiency ELISA Kit; FactorIX ELISA Kit; FIX ELISA Kit; Haemophilia B ELISA Kit; HEMB ELISA Kit; MGC129641 ELISA Kit; MGC129642 ELISA Kit; P19 ELISA Kit; Plasma Thromboplastic Component ELISA Kit; Plasma thromboplastin component ELISA Kit; PTC ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma
  • 檢測范圍:
    25 ng/ml-400 ng/ml
  • 靈敏度:
    12.5 ng/ml
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Blood Coagulation
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:
     
  • 線性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human FⅨ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
      Sample Serum(n=4)    
    1:1 Average % 95    
    Range % 89-99    
    1:2 Average % 102    
    Range % 96-107    
    1:4 Average % 92    
    Range % 87-98    
    1:8 Average % 86    
    Range % 81-92    
  • 回收率:
     
  • 標準曲線:
     
  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

靶點詳情

  • 功能:
    Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.
  • 基因功能參考文獻:
    1. available to predict the inhibitory activity on FIXa. On the basis of pharmacophore modeling, molecular docking, and 3D-QSAR modeling screening, six molecules are PMID: 29724133
    2. Report induced pluripotent stem cell model characterizing mutated F9 mRNA in hemophilia B. PMID: 28834196
    3. genetic association studies in cohort of patients in Switzerland: Data suggest that F9 propeptide mutation-associated hypersensitivity to vitamin K antagonist anticoagulants is rare phenomenon; F9 propeptide mutation Ala37Thr confers high sensitivity to warfarin. PMID: 29450643
    4. Higher FIX antigen levels are associated with incident coronary heart disease in blacks but not in whites; the association of FXI levels with ischemic stroke is slightly attenuated after adjusting for stroke risk factors. PMID: 28393470
    5. a computational approach was conducted to select suitable location(s) for introducing new N-glycosylation sites into the human coagulation factor IX. PMID: 27356208
    6. The pathogenic basis for one synonymous mutation (Val107Val) in the F9 gene associated with haemophilia B was determined. PMID: 28007939
    7. caspase-3 inhibitors also suppressed the attenuation of cell adhesion and phosphorylation of p38 MAPK by EGF-F9. Our data indicated that EGF-F9 activated signals for apoptosis and induced de-adhesion in a caspase-3 dependent manner. PMID: 27129300
    8. Specific factor IX mRNA and protein features that favor drug-induced readthrough over recurrent nonsense mutations have been reported. PMID: 28196793
    9. Here we optimize the transient transfection of HEK293T/17 cells for the production of AAV human factor IX in a disposable fixed-bed bioreactor, the iCELLis((R)) Nano (PALL Corporation). PMID: 27229773
    10. Thus, splicing and protein alterations contribute to define at the molecular level the disease-causing effect of a number of exonic mutations in coagulation FIX exon 5. In addition, our results have a significant impact in the development of splicing-switching therapies in particular for mutations that affect both splicing and protein function PMID: 27227676
    11. This study confirms the high heterogeneity of molecular defects leading to hemophilia B in Belgium. Six missense variants and 1 in-frame deletion, previously unreported, were predicted to affect FIX protein function. PMID: 27865967
    12. this study shows that targeted high-throughput sequencing is an effective technique to detect the F9 gene mutations in hemophilia patients PMID: 27292088
    13. Patient 1 had a 149-kb deletion with breakpoints 90-kb upstream and 30-kb downstream from F9. Patients 2 and 3 showed 273-kb and 1.19-Mb deletions respectively. Patient 4 had two deleted regions: a 1663-bp deletion 1.34-Mb upstream from F9 and a 7.2-Mb deletion including F9. PMID: 26686734
    14. Factor IX mutation was found in every family: eight had large deletions, three had small deletions (<10 base pair) and 102 had single base pair substitutions (69 missense, 26 nonsense, four splice site and three promoter). PMID: 26612714
    15. Data suggest that coagulation factor IX (hFIX) minigene containing beta-globin (hBG) introns could represent a particular interest in stem cell-based gene therapy of hemophilias. PMID: 26928674
    16. miR-128 and miR-125 could help to increase the nonsense-mutant F9 levels by repressing nonsense-mediated mRNA decay. PMID: 27133073
    17. In 293T cells, the addition of 0.5 mM Ca(+2) and 1 mM Mg(+2) resulted in higher recombinant human Factor IX concentration. SK-Hep-1 cell line proved to be very effective in rhFIX production, and it can be used as a novel biotechnological platform for the production of recombinant proteins. PMID: 26802680
    18. Mutations were revealed in 56 unrelated patients with hemophilia B in this study by using direct sequencing of factor IX gene functionally important fragments. PMID: 27529981
    19. The Cys109Tyr F9 mutation found in two siblings and their mother, is a missense mutation previously described in two patients with hemophilia B, but first in Korea. PMID: 25402191
    20. Differentiation studies demonstrated osteogenic (but not chondrogenic or adipogenic) differentiation capability and efficient FIX secretion of the enclosed MSCs in the fibronectin-alginate suspension culture. PMID: 24564349
    21. Selective disruption of exosite-mediated regulation of factor IX by heparin and antithrombin can be achieved with preserved or enhanced thrombin generation capacity. PMID: 25851619
    22. study revealed six unique and unreported changes in the F9 gene among haemophilia B patients from Macedonia and Bulgaria PMID: 25582609
    23. We conclude that the nature of the F9 gene mutation may be an important risk factor for the development of inhibitors. PMID: 25470321
    24. Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors. PMID: 25224783
    25. Data suggest that Gly317 plays role in normal catalytic function for FIX/FIXa in the clotting cascade; mutations in Gly317 (G317R, G317E) result in variable severity of bleeding in hemophilia B patients. PMID: 26023895
    26. repetitive elements and non-B DNA forming motifs contribute to deletion mutations in severe haemophilia B PMID: 24816826
    27. Various factor IX mutations have been identified in Chinese hemophilia B patients. PMID: 24261420
    28. 11 FIX gene mutations (8 point mutations, 2 small deletions/insertions, and 1 large deletion), including two novel mutations (exon6 c.687-695, del 9 mer and c.460-461, ins T) were found. PMID: 24656159
    29. Report oral FIX gene transfer strategy for hemophilia B. PMID: 24679056
    30. This review discuss structural features of factor XIa that are required for factor IX activation, and the importance of the protease's dimeric structure. [review] PMID: 24759143
    31. Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients. PMID: 24498168
    32. Thrombin-mediated, TAFI-dependent down-regulation of fibrinolysis provides new clues for explaining the heightened thrombotic risk in subjects carrying the FIX-Padua mutation. PMID: 24136406
    33. 87 unique mutations (9 novel) were found in 225 American hemophilia B patients. c.316G>A, c.1025C>T, and c.1328T>A accounted 37.1%. Only those with large deletions and nonsense mutations had inhibitors. PMID: 24375831
    34. The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D. PMID: 24068708
    35. The results suggest the Omega-loop of FIX binds to an area on FXIa composed of residues from the N-terminus and C-terminus of the A3 domain. These residues are buried in zymogen FXI, and must be exposed upon conversion to FXIa to permit FIX binding. PMID: 23617568
    36. Report interactive database providing insights into mechanisms of hemophilia B. PMID: 23617593
    37. Data indicate that five nanofilters can be used interchangeably to yield a high purity Coagulation Factor IX product. PMID: 23410583
    38. Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events. PMID: 24124147
    39. Letter: report factor IX activity/antigen ratio in relation to risk of first unprovoked venous thromboembolism. PMID: 23446552
    40. Mutations at the -5/-6 site (nucleotides -5 and -6 relative to the transcription start site, designated 1) of the F9 promotor account for the majority of hemophilia B Leyden cases and disrupt the binding of ONECUT transcription factors. PMID: 23472758
    41. Results demonstrate the role of plasticity in regulating FIXa function with respect to discrimination of extended substrate sequences. PMID: 22212890
    42. structural features within residues of the 39-loop contribute to the resistance of FIXa to inhibition by plasma inhibitors ZPI and TFPI. PMID: 23530052
    43. Report causative F9 mutations in Argentine families with hemophilia B and determine mutation-associated FIX inhibitor risks. PMID: 23093250
    44. The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa. PMID: 23054460
    45. investigated the contribution of the NH2-terminal EGF-domain (EGF1) to the recognition specificity of intrinsic tenase by constructing an EGF1 deletion mutant and characterising the properties of the mutant in kinetic, direct binding and FRET assays PMID: 23014580
    46. The results suggest that information at the mRNA level as well as conservation of amino acids of coagulation factor IX correlate well with disease severity. PMID: 22639855
    47. Results indicate that fXIa activates fIX by an exosite- and Ca(2+)-mediated release-rebind mechanism. PMID: 22961984
    48. Western blotting of plasma from FIX deficient (Hemophilia B) patients revealed traces of full-length FIX for the p.R294* and p.R298* mutations, but not for the p.L103* mutation that triggered major FIX mRNA decay. PMID: 22618954
    49. factor IX mutations were identified in either the exon or intronic regions in haemophilia B patients in Malaysia; one novel mutation, 6660_6664delTTCTT was identified in siblings with moderate form of haemophilia B PMID: 22870602
    50. The F9 mutations were heterogenous and the missense mutations were the most prevalent gene defects in Chinese haemophilia B patients. PMID: 22544209

    顯示更多

    收起更多

  • 相關疾病:
    Hemophilia B (HEMB); Thrombophilia, X-linked, due to factor IX defect (THPH8)
  • 亞細胞定位:
    Secreted.
  • 蛋白家族:
    Peptidase S1 family
  • 組織特異性:
    Detected in blood plasma (at protein level). Synthesized primarily in the liver and secreted in plasma.
  • 數據庫鏈接:

    HGNC: 3551

    OMIM: 300746

    KEGG: hsa:2158

    STRING: 9606.ENSP00000218099

    UniGene: Hs.522798



主站蜘蛛池模板: av国産精品毛片一区二区网站 | 日日拍夜夜嗷嗷叫|日日摸| 亚洲成av人片天堂网老年人| 男人把女人桶到爽免费应用| 久久av无码精品人妻糸列| 精品久久人人妻人人做精品| 18禁无遮挡无码网站免费| 高清国产亚洲欧洲av综合一区| 色五月丁香六月欧美综合| 18禁美女裸体免费网站| 国产成人综合亚洲色就色| 狠狠做久久深爱婷婷| 国产在线一区二区三区四区五区| 综合 欧美 亚洲日本| 亚洲中文字幕精品久久| 免费人成又黄又爽的视频 | 亚洲成av人片一区二区三区| 国产麻豆剧果冻传媒白晶晶| 国产精品亚洲欧美大片在线看| 欧美精品欧美人与动人物牲交| 四十如虎的丰满熟妇啪啪| 九九视频免费精品视频| 非洲黑人最猛性xxxx交| 国产精品成人免费999| 免费两性的视频网站| 久久性色av亚洲电影| 国产92成人精品视频免费| 无码尹人久久相蕉无码| 在线|国产精品女主播阳台| 无码av免费网站| 伊人色综合久久天天五月婷| 欧美韩中文精品有码视频在线| 亚欧日韩欧美网站在线看| 波多野结衣乳巨码无在线观看| 久久婷婷激情综合色综合俺也去| 狠狠色噜噜狠狠狠888777米奇| 99亚洲乱人伦aⅴ精品| 999国内精品永久免费视频| 亚洲欧洲自拍拍偷精品 美利坚| 国产精品玖玖玖在线| 99精品久久毛片a片|